Strategic Advisory Committee

Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

With leading authorities in healthcare and public policy, the SAC committee provides strategic direction and guidance with regards to Hilleman’s overarching mission and vision. With their deep knowledge and expertise in biotechnology, vaccines, global health and policy, the SAC works alongside the Hilleman Labs management team in creating new avenues for public health impact by developing affordable vaccines.

Dr. Ted Bianco

Chairman - Strategic Advisory Committee

Biography

Dr. David Kaslow

Member - Strategic Advisory Committee

Biography

Dr. Kevin Johnson

Member - Strategic Advisory Committee

Biography

Ms. Mahima Datla

Member - Strategic Advisory Committee

Biography

Prof. Andrew J Pollard

Member - Strategic Advisory Committee

Biography

Dr. Martin Howell Friede

Observer - Strategic Advisory Committee

Biography
close

Dr. Ted Bianco

Chairman - Startegic Advisory Committee

Dr. Bianco is a global leader in public health research, advocacy and policy. He is also a founding member of Hilleman Labs.

Dr. Bianco was the Wellcome Trust Executive Board Member for Sustaining Health. He has 25 years experience in biomedical research, specialising in tropical medicine and infectious disease. He obtained his PhD at the London School of Hygiene and Tropical Medicine and subsequently worked at the Walter and Eliza Hall Institute in Melbourne, Imperial College of Science, Technology and Medicine in London and the Liverpool School of Tropical Medicine, where he was the Walter Myers Professor of Parasitology. He joined the Wellcome Trust in 1999 as Head of the Centres and Major Initiatives department and subsequently spent 11 years as Director of Innovations. Dr. Bianco is an Honorary Professor of the Liverpool School of Tropical Medicine.

close

Dr. David Kaslow

Member - Strategic Advisory Committee

David Kaslow is MD, Vice President for Essential Medicines at Path, which includes Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). As the director of CVIA, he leads the development and introduction of lifesaving vaccines for the most vulnerable children and communities around the world.

Dr. Kaslow has more than 25 years of experience in vaccine research and development. Before joining PATH in 2012 as director of MVI's work to drive the development of safe and effective vaccines against malaria, he held key advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines. Prior to that, he oversaw project leadership and management of Merck Research Laboratories’ vaccine pipeline and founded the Malaria Vaccine Development Unit at the National Institutes of Health.

As a basic research scientist, Dr. Kaslow completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He also has directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, Dr. Kaslow has contributed to the vaccine application of tools originally developed for gene therapy. He holds or coholds more than a dozen patents and has published more than 150 scientific papers.

Dr. Kaslow received his medical degree from the University of California, San Francisco.

close

Dr. Kevin Johnson

Member - Strategic Advisory Committee

Kevin is a co-founder and Partner at Medicxi. Prior to co-founding Medicxi, Dr. Johnson was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Dr. Johnson spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently chairman of Levicept Ltd., Apcintex and Crescendo Biologics as well as being a board member of several other startups.

Prior to joining Index, Dr. Johnson was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now in the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Dr. Johnson was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.

Dr. Johnson received a BSc in Molecular Biology from Edinburgh University and a PhD from Cambridge University.

close

Ms. Mahima Datla

Member - Strategic Advisory Committee

Mahima Datla is Managing Director of Biological E. Limited who directly oversees strategic operations within the organization and leads the public policy work.

Ms. Datla has been working with BE for the past 18 years and has served in various capacities across a diverse range of functions, including Biotechnology & Projects; Operations and Strategic Business Development. Under Ms. Datla’s leadership, BE has demonstrated a solid growth given the successful WHO pre-qualification and launch of the Pentavalent and JE vaccines.

Apart from Biological E, Ms. Datla has served on the steering committee of DCVMN (Developing Countries Vaccine Manufacturers Network) and is currently the President of the alliance. She is a member of FICCI and CII National Biotech committees in India. She has also been on the board of GAVI (Global alliance for vaccines and immunization) from 2011 to 2014. She is currently a GHIT (Global Health Innovative Technology) fund board member, which is a Japanese government innovation healthcare fund for improving global access to healthcare.

Ms. Datla is a graduate of Webster University, London with a degree in Business Administration Management.

close

Prof. Andrew J Pollard

Member - Strategic Advisory Committee

Andrew J Pollard, FRCPCH PhD FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford since 2001.

Prof. Pollard research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid in Nepal, Bangladesh and Malawi, and co-leads typhoid vaccine impact studies at these sites. He has supervised 32 PhD students and his publications includes over 450 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE committee.

Prof. Pollard received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 and the ESPID Distinguished Award for Education & Communication in 2015.

close

Dr. Martin Howell Friede

Observer - Strategic Advisory Committee

Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr Friede provides leadership to WHO’s activities on vaccine research including development of vaccine research policies, strategies and priorities. Prior to this position he held several positions within WHO including leading the organization’s technology transfer activities as well as leading the research into therapeutic interventions for Ebola.

Prior to joining WHO, Dr Friede held several senior management positions in the vaccine industry. Dr Friede earned his Ph.D. in Biochemistry from the University of Cape Town.